Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study

Yuemei Hu, Kai Chu, Nathalie Lavis, Xiaoling Li, Bill Liang, Shuzhen Liu, Ming Shao, Jean-Denis Shu, Cynthia Tabar, Sandrine Samson, Yuemei Hu, Kai Chu, Nathalie Lavis, Xiaoling Li, Bill Liang, Shuzhen Liu, Ming Shao, Jean-Denis Shu, Cynthia Tabar, Sandrine Samson

Abstract

Seasonal influenza causes substantial morbidity and mortality in China, which largely results from limited vaccine accessibility and poor vaccination coverage. Since 2013, Sanofi Pasteur's facilities in Shenzhen, China have produced a trivalent inactivated influenza vaccine (Shz-IIV3) for each influenza season according to Chinese pharmacopeia requirements. However, the immunogenicity of Shz-IIV3 has not been compared to existing Chinese trivalent inactivated influenza vaccines (IIV3s). Here, we describe the results of a phase IV, observer-blind, randomized study to evaluate whether the immunogenicity of Shz-IIV3 was non-inferior to a comparator IIV3 (Hualan Biological Engineering Inc) also manufactured and licensed in China. Healthy adults aged 18-59 years were randomly assigned in a 1:1 ratio to receive a single 0.5-mL intramuscular injection of the 2017-2018 Northern Hemisphere formulation of Shz-IIV3 (n = 800) or the comparator IIV3 (n = 799). Between baseline and day 28 after vaccination, hemagglutination inhibition titers for the three vaccine strains increased by at least 4-fold and were of similar magnitude in Shz-IIV3 and comparator IIV3 recipients. The rate of seroconversion or significant increase in titers was 62% to 92% in Shz-IIV3 recipients, and 63% to 91% in comparator IIV3 recipients. Post-vaccination hemagglutination inhibition titers and seroconversion rates for Shz-IIV3 were statistically non-inferior to the comparator IIV3 for all three influenza vaccine strains. Rates of solicited and unsolicited vaccine-related adverse events were similar between the two vaccine groups. These results demonstrated that Shz-IIV3 was as immunogenic and safe in adults as a comparator Chinese IIV3, and support the continued use of Shz-IIV3 in China.

Keywords: China; Trivalent influenza vaccines; immunogenicity; influenza; reactogenicity; safety; vaccination.

References

    1. World Health Organization Influenza (seasonal). 2018. January 31 [accessed 2018 Aug 17] ).
    1. Feng L, Shay DK, Jiang Y, Zhou H, Chen X, Zheng Y, Jiang L, Zhang Q, Lin H, Wang S, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003–2008. Bull World Health Organ. 2012;90(4):279–88B. doi:10.2471/blt.11.096958.
    1. Yu H, Feng L, Viboud CG, Shay DK, Jiang Y, Zhou H, Zhou M, Xu Z, Hu N, Yang W, et al. Regional variation in mortality impact of the 2009 A(H1N1) influenza pandemic in China. Influenza Other Respir Viruses. 2013;7(6):1350–60. doi:10.1111/irv.12121.
    1. Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, Peng Y, Yang H, Luo J, Zheng J, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010–2012. Influenza Other Respir Viruses. 2014;8(1):53–65. doi:10.1111/irv.12205.
    1. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62.
    1. World Health Organization Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76.
    1. Feng L, Yang P, Zhang T, Yang J, Fu C, Qin Y, Zhang Y, Ma C, Liu Z, Wang Q, et al. Technical guidelines for the application of seasonal influenza vaccine in China (2014–2015). Hum Vaccin Immunother. 2015;11(8):2077–101. doi:10.1080/21645515.2015.1027470.
    1. Zhou L, Su Q, Xu Z, Feng A, Jin H, Wang S, Feng Z.. Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season (2009/10 to 2011/12). PLoS One. 2013;8(9):e73724. doi:10.1371/journal.pone.0073724.
    1. Zhang Y, Muscatello DJ, Wang Q, Yang P, Wu J, MacIntyre CR. Overview of influenza vaccination policy in Beijing, China: current status and future prospects. J Public Health Policy. 2017;38(3):366–79. doi:10.1057/s41271-017-0079-7.
    1. Mo Z, Nong Y, Liu S, Shao M, Liao X, Go K, Lavis N. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China. Hum Vaccin Immunother. 2017;13(6):1–7. doi:10.1080/21645515.2017.1285475.
    1. Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31(47):5572–78. doi:10.1016/j.vaccine.2013.08.069.
    1. Committee for Proprietary Medicinal Products (CPMP) Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 1996.
    1. European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) Guideline on the choice of the non-inferiority margin. 2005. July 27 [accessed 2019 Jan 3] .
    1. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72.
    1. International Conference on Harmonisation Clinical safety data management: definitions and standards for expedited reporting E2A, Geneva, Switzerland. 1994.
    1. Grohskopf LA, Shay DK, Shimabukuro TT, Sokolow LZ, Keitel WA, Bresee JS, Cox NJ. Prevention and control of seasonal influenza with vaccines. Recommendations of the advisory committee on immunization practices–United States, 2013–2014. MMWR Recomm Rep. 2013;62:1–43.
    1. Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, Giezeman K, de Bruijn I. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China. Vaccine. 2008;26(35):4579–84. doi:10.1016/j.vaccine.2008.05.082.
    1. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, vaccine adverse event reporting system (VAERS), July 1, 2013-May 31, 2015. Vaccine. 2016;34(22):2507–12. doi:10.1016/j.vaccine.2016.03.048.
    1. Giezeman KM, Nauta J, de Bruijn IA, Palache AM. Trivalent inactivated subunit influenza vaccine influvac: 25-year experience of safety and immunogenicity. Vaccine. 2009;27(18):2414–17. doi:10.1016/j.vaccine.2009.02.008.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj